<DOC>
	<DOCNO>NCT01052584</DOCNO>
	<brief_summary>In stdy , patient age 6 month symptomatic malaria present health center enrol treatment artemether-lumefantrine P. falciparum infection , either artemether-lumefantrine chloroquine P. vivax infection . Clinical , parasitologic , hematologic parameter monitor P. falciparum P. vivax infection 42-day follow-up period , used evaluate drug efficacy . Results research study use assist Ethiopia assess current national malaria drug policy .</brief_summary>
	<brief_title>Ethiopia Malaria Therapeutic Efficacy Study</brief_title>
	<detailed_description>Following rapid development significant drug resistance Plasmodium falciparum ( Pf ) chloroquine sulfadoxine-pyrimethamine ( first line therapy Ethiopia 1998-2004 ) , artemether- lumefantrine ( Coartem AL ) adopt first line therapy Ethiopia 2004 . According current national malaria diagnosis treatment guideline , first-line treatment uncomplicated falciparum infection AL . First-line treatment Plasmodium vivax ( Pv ) chloroquine ( CQ ) alone without primaquine therapy malarious area . For clinical infection without laboratory confirmation , AL effective Pf Pv first-line treatment . Thus , Ethiopia , treatment malaria without laboratory confirmation occur frequently , Pv often treat AL standard care . Furthermore , World Health Organization ( WHO ) recommend AL treatment Pv , AL adopt first-line treatment Pf . Now wide-spread use AL CQ , propose conduct antimalarial efficacy study monitor effectiveness therapy Ethiopia determine efficacious drug remain . This information inform future policy change respect appropriate antimalarial strategy . The simple universally accepted measure test antimalarial drug treatment efficacy , standardized procedure outline World Health Organization Assessment monitor antimalarial drug efficacy treatment uncomplicated falciparum malaria WHO Monitoring antimalarial drug resistance , follow .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Slideconfirmed infection P. falciparum , parasitemia 1,000100,000 asexual forms/ μl slide confirm infection P. vivax &gt; 250 asexual forms/ μl Lives within 20 km enrol health facility Weight ≥ 5.0 kg Axillary temperature ≥ 37.5º C history fever previous 24 48 hour P. falciparum P. vivax infection , respectively Patient caregiver agree blood draw return visit . General danger sign symptom severe malaria Signs symptom severe malnutrition , define weightforage ≤ 3 standard deviation mean ( NCHS/WHO normalize reference value ; Slide confirm infection Plasmodium spp . besides falciparum/vivax mixed plasmodium infection Severe anemia , define Hg &lt; 5 g/dl Known hypersensitivity drug evaluate Presence febrile condition cause disease malaria Serious chronic medical condition ( cardiac , renal , hepatic disease , sickle cell disease , HIV/AIDS ) Pregnant breastfeed woman . Children weigh less 5 kilogram .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>malaria</keyword>
	<keyword>therapeutic efficacy</keyword>
	<keyword>vivo</keyword>
	<keyword>artemether lumefantrine</keyword>
	<keyword>coartem</keyword>
	<keyword>chloroquine</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Plasmodium vivax</keyword>
</DOC>